E-viri
Recenzirano
-
Scanio, Marc J.C.; Searle, Xenia B.; Liu, Bo; Koenig, John R.; Altenbach, Robert J.; Gfesser, Gregory A.; Bogdan, Andrew; Greszler, Stephen; Zhao, Gang; Singh, Ashvani; Fan, Yihong; Swensen, Andrew M.; Vortherms, Timothy; Manelli, Arlene; Balut, Corina; Gao, Wenqing; Yong, Hong; Schrimpf, Michael; Tse, Chris; Kym, Philip; Wang, Xueqing
Bioorganic & medicinal chemistry letters, 09/2022, Letnik: 72Journal Article
Display omitted Cystic fibrosis (CF) is an autosomal recessive disease resulting from mutations on both copies of the CFTR gene. Phenylalanine deletion at position 508 of the CFTR protein (F508del-CFTR) is the most frequent mutation in CF patients. Currently, the most effective treatments of CF use a dual or triple combination of CFTR correctors and potentiators. In triple therapy, two correctors (C1 and C2) and a potentiator are employed. Herein, we describe the identification and exploration of the SAR of a series of 4-aminopyrrolidine-2-carboxylic acid C2 correctors of CFTR to be used in conjunction with our existing C1 corrector series for the treatment of CF.
